Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.55 |
| ▸ | MDM4 | O15151 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14265316 | 1.00 | CASP3 (0.55) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29402145 | 1.00 | CASP3 (0.55) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29400810 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL14265315 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL25268084 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL25206792 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL16060727 | 0.91 | CASP3 (0.50) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29400295 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL1959804 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 | |
| SCHEMBL29666630 | 0.90 | CASP3 (0.48) | CASP3MDM4TP53KMT2AMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-20140039153-A1 | CANCER IMAGING AND TREATMENT | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140039153-A1 | CANCER IMAGING AND TREATMENT | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20100240072-A1 | Cancer Imaging and Treatment | TECHNISCHE UNIVERSITAT MUNCHEN (DE) | 2010-09-23 | — | — | US | disclosed |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | CHRONTECH PHARMA AB (SE) | 2008-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039153-A1 | CANCER IMAGING AND TREATMENT | PNISR, S1PR3, S1PR1 | CASP3 1977/4885MDM4 1915/4885TP53 60/4885 |
| US-20080076824-A1 | modified glycinamides: Valine-alphahydroxy-glycinamide | GALE, ENGASE, UGGT1 | CASP3 2910/4885MDM4 1166/4885TP53 1635/4885 |
| US-20100240072-A1 | Cancer Imaging and Treatment | PNISR, S1PR3, S1PR1 | CASP3 1977/4885MDM4 1915/4885TP53 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.